Home Biosimilar Antibodies Immunology & Inflammation Mucin Gatipotuzumab (Anti-MUC1)
For research use only. Not for use in humans.

Gatipotuzumab (Anti-MUC1)

Synonyms: null

Gatipotuzumab (Anti-MUC1) is a humanized monoclonal antibody recognizing the tumor-specific epitope of mucin-1 (TA-MUC1) with potential antineoplastic activity. MW: 146.58 KD.

Gatipotuzumab (Anti-MUC1)

Quality Control

Batch: A287901 Purity: 99% Protein concentration: 6.97mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Gatipotuzumab (Anti-MUC1) is a humanized monoclonal antibody recognizing the tumor-specific epitope of mucin-1 (TA-MUC1) with potential antineoplastic activity. MW: 146.58 KD.
References

Product Details

CAS No. 1264737-26-9
Molecular Weight 146.58
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05812326 COMPLETED Drug: AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells Advanced Breast Cancer; Breast Neoplasm Malignant Female Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 2019-05-17 PHASE1; PHASE2
NCT03706326 UNKNOWN Advanced Esophageal Cancer The First Affiliated Hospital of Guangdong Pharmaceutical University 2018-09-28 PHASE1; PHASE2
NCT03525782 UNKNOWN Drug: PD-1 mAb Lung Neoplasm Malignant; Non-small Cell Lung Cancer The First Affiliated Hospital of Guangdong Pharmaceutical University 2018-02-01 PHASE1; PHASE2
NCT03360734 COMPLETED Drug: First part: Gatipotuzumab and Tomuzotuximab; Second pa Solid Tumor, Adult Glycotope GmbH 2017-11-02 PHASE1
NCT02544880 COMPLETED Drug: Tadalafil Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer Donald T. Weed, MD, FACS 2016-04-25 PHASE1
NCT02617134 UNKNOWN Malignant Glioma of Brain; Colorectal Carcinoma; Gastric Carcinoma PersonGen BioTherapeutics (Suzhou) Co., Ltd. 2015-11 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2023-04-13)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.